Consultant, Michael Corcoran, from Hill Dickinson’s London corporate team has recently advised long-standing Canadian Securities Exchange listed client, Portage Biotech Inc. (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U) (Portage) on its participation in a new joint venture project with the University of Glasgow to develop more effectively targeted drugs to treat chronic conditions including cancer.

Portage is providing an undisclosed funding injection to the new business, called Portage Glasgow Limited, along with a limited license to its CellPorter™ peptide delivery technology.

Portage Glasgow will build on the University of Glasgow’s expertise in precision medicine, a fast-developing area of treatment which aims to provide better outcomes for patients by providing drugs particularly tailored to their specific needs. The University of Glasgow’s Professor George Bailie will provide input on therapeutic peptides and also allow access to a therapeutic peptide discovery platform.

Professor Baillie said: ‘The combination of Portage’s unique peptide delivery system and my group’s expertise in targeted disruption of specific protein complexes brings real potential to make headway in discovering new therapeutics against a variety of diseases with unmet need. I am truly excited by the possibilities.’

Ballie is the Professor of Molecular Pharmacology at the University of Glasgow’s Institute of Cardiovascular and Medical Sciences and worked for 15 years on publically and privately-funded research in phosphodiesterase enzymes and protein-protein interactions.

Dr. Declan Doogan, chief executive officer and director of Portage Biotech commented: ‘This is a great example of a collaboration between commercial drug developers and academic researchers who have the potential to deliver truly cutting edge much needed treatments to patients worldwide. I am excited to be associated with this Glasgow based enterprise.’